Gaurav Shah bought $102k of RCKT
CEO at ROCKET PHARMACEUTICALS, INC.. 20,000 shares at an average of $5.08, traded Apr 10, 2025, filed Apr 14, 2025.
Score components
- +25RoleCEO
- +10Trade size$102k at market
- 0Relative to holdingsHoldings up 2.6%
- +18Price context3% above the 52-week low; 77% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-013804, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 10, 2025 | POpen-market purchase Common Stock | +20,000 | $5.08 | $102k | 792,680 | Apr 14, 2025 |
Related signals
Other insiders at ROCKET PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $256k 75,364 shares | -11% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $3,240 1,086 shares | -2% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $4,910 1,646 shares | -0% | |
| 40Moderate | ROCKET PHARMACEUTICALS, INC. | Gaurav Shah CEO | $19k 6,276 shares | -1% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Jonathan David Schwartz See Remarks | $7,592 2,545 shares | -1% | |
| 35Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $115k 28,918 shares | -30% | |
| 35Weak | RCKTbuy ROCKET PHARMACEUTICALS, INC. | Elisabeth Bjork director | $34k 10,000 shares | +33% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $3,224 1,060 shares | -2% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $4,839 1,592 shares | -1% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Jonathan David Schwartz See Remarks | $7,561 2,485 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.